The study evaulating potential biomarkers in patients with advanced hepatocellular carcinoma treated with sorafenib using circulating tumour DNA (ctDNA)
Latest Information Update: 11 Oct 2017
Price :
$35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Pharmacodynamics
- 11 Oct 2017 New trial record
- 12 Sep 2017 Results assessing the biomarker in patients treated with sorafenib for advanced hepatocellular carcinoma (HCC) using circulating tumour DNA (ctDNA), were presented at the 42nd European Society for Medical Oncology Congress.